CO6410309A2 - Compuestos que expanden las celulas madre hematopoieticas - Google Patents

Compuestos que expanden las celulas madre hematopoieticas

Info

Publication number
CO6410309A2
CO6410309A2 CO11058070A CO11058070A CO6410309A2 CO 6410309 A2 CO6410309 A2 CO 6410309A2 CO 11058070 A CO11058070 A CO 11058070A CO 11058070 A CO11058070 A CO 11058070A CO 6410309 A2 CO6410309 A2 CO 6410309A2
Authority
CO
Colombia
Prior art keywords
compounds
mother cells
cells
expand hematopoietic
hematopoietic mother
Prior art date
Application number
CO11058070A
Other languages
English (en)
Inventor
Michael Cooke
Shifeng Pan
Peter G Schultz
Anthony E Boitano
Xing Wang
Yongqin Wan
John Edward Tellew
Original Assignee
Irm Llc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42111339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6410309(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Scripps Research Inst filed Critical Irm Llc
Publication of CO6410309A2 publication Critical patent/CO6410309A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a compuestos y composiciones para expandir el número de células CD34+ para trasplante. La invención se refiere además a una población celular que comprende células madre hematopoiéticas (HSCs) expandidas, y a su uso en trasplante autólogo o alogénico para el tratamiento de los pacientes con enfermedades de inmunodeficiencia y autoinmunes heredadas y diversos trastornos hematopoiéticos, con el fin de reconstituir los linajes de células hematopoiéticas y las defensas del sistema inmunitario.
CO11058070A 2008-10-30 2011-05-11 Compuestos que expanden las celulas madre hematopoieticas CO6410309A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10982108P 2008-10-30 2008-10-30
US24276509P 2009-09-15 2009-09-15

Publications (1)

Publication Number Publication Date
CO6410309A2 true CO6410309A2 (es) 2012-03-30

Family

ID=42111339

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11058070A CO6410309A2 (es) 2008-10-30 2011-05-11 Compuestos que expanden las celulas madre hematopoieticas

Country Status (41)

Country Link
US (4) US8927281B2 (es)
EP (2) EP3524604B1 (es)
JP (1) JP5390626B2 (es)
KR (1) KR101434719B1 (es)
CN (1) CN102203096B (es)
AR (1) AR074063A1 (es)
AU (1) AU2009317898B2 (es)
BR (1) BRPI0921799B8 (es)
CA (3) CA2943540C (es)
CL (2) CL2009002010A1 (es)
CO (1) CO6410309A2 (es)
CR (1) CR20110192A (es)
CU (1) CU24495B1 (es)
CY (1) CY1121857T1 (es)
DK (1) DK2350078T3 (es)
DO (1) DOP2011000114A (es)
EA (1) EA019872B1 (es)
EC (1) ECSP11011090A (es)
ES (2) ES2948567T3 (es)
GE (1) GEP20146053B (es)
HN (1) HN2011001195A (es)
HR (1) HRP20191238T1 (es)
HU (1) HUE044802T2 (es)
IL (1) IL212368A (es)
JO (1) JO3593B1 (es)
LT (1) LT2350078T (es)
MA (1) MA32828B1 (es)
MX (1) MX347834B (es)
MY (1) MY155137A (es)
NI (1) NI201100083A (es)
NZ (1) NZ592435A (es)
PE (1) PE20100362A1 (es)
PL (1) PL2350078T3 (es)
PT (1) PT2350078T (es)
RS (1) RS59027B1 (es)
SI (1) SI2350078T1 (es)
SM (1) SMP201100024B (es)
SV (1) SV2011003888A (es)
TN (1) TN2011000174A1 (es)
TW (1) TWI532486B (es)
WO (1) WO2010059401A2 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2402341B1 (en) * 2007-03-28 2017-10-25 Saniona A/S Purinyl derivatives and their use as potassium channel modulators
AU2008231695B2 (en) * 2007-03-28 2013-03-28 Novartis Ag Purinyl derivatives and their use as potassium channel modulators
EP2279188B1 (en) * 2008-05-30 2015-01-28 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
EP2344501A1 (en) * 2008-09-26 2011-07-20 NeuroSearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
WO2010034707A1 (en) * 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2647697B1 (en) * 2010-12-01 2016-08-24 Nissan Chemical Industries, Ltd. Method for producing hematopoietic stem cells using pyrazole compound
WO2012102937A2 (en) * 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
CA2837207A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
US20140205582A1 (en) * 2011-07-06 2014-07-24 Cellerant Therapeutics, Inc. Megakaryocyte progenitor cells for production of platelets
WO2013019857A2 (en) * 2011-08-01 2013-02-07 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
RU2640913C2 (ru) * 2011-09-07 2018-01-12 Дойчес Кребсфоршунгсцентрум Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
PL2807165T3 (pl) * 2012-01-27 2019-09-30 Université de Montréal Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych
CN104204192A (zh) 2012-02-13 2014-12-10 加米达细胞有限公司 间充质干细胞调理的基质及其产生和使用方法
JP6223443B2 (ja) 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
US9567569B2 (en) * 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
WO2014110020A1 (en) 2013-01-08 2014-07-17 Fred Hutchinson Cancer Research Center Compositions and methods for expansion of embryonic hematopoietic stem cells
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US9757378B2 (en) * 2013-05-17 2017-09-12 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
AU2014338555B2 (en) * 2013-10-24 2019-10-10 Fondazione Telethon Method
CN105873952A (zh) 2013-10-31 2016-08-17 弗莱德哈钦森癌症研究中心 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
EP3247808B1 (en) 2015-01-21 2021-05-05 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
EP3995142A3 (en) 2015-04-29 2022-08-24 Fred Hutchinson Cancer Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
NZ741612A (en) * 2015-10-15 2022-12-23 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
SG11201802895QA (en) 2015-10-23 2018-05-30 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
TWI812584B (zh) 2015-10-30 2023-08-21 美國加利福尼亞大學董事會 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法
KR20180103923A (ko) * 2015-12-28 2018-09-19 노파르티스 아게 혈색소병증의 치료를 위한 조성물 및 방법
JP7118340B2 (ja) 2016-04-14 2022-08-16 フレッド ハッチンソン キャンサー センター 標的化核酸ナノ担体を使用して治療用細胞をプログラムするための組成物及び方法
KR20190005964A (ko) * 2016-05-07 2019-01-16 셀룰래리티, 인코포레이티드 천연 킬러 세포를 이용한 급성 골수성 백혈병 및 다발성 골수종의 치료 방법
US11040035B2 (en) 2016-05-25 2021-06-22 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
CN109890805B (zh) * 2016-08-18 2023-04-04 新加坡国立大学 用于造血干细胞和祖细胞的产生、增殖和分化的取代的唑衍生物
EP3519577A1 (en) 2016-09-28 2019-08-07 Novartis AG Porous membrane-based macromolecule delivery system
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
CA3057159A1 (en) 2017-04-12 2018-10-18 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and uses thereof
CA3059939A1 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
US11548867B2 (en) 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
US11878001B2 (en) 2017-07-31 2024-01-23 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
US20200283444A1 (en) * 2017-08-02 2020-09-10 Northwestern University Substituted fused pyrimidine compounds and uses thereof
WO2019067792A1 (en) 2017-09-28 2019-04-04 Celularity, Inc. TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY
BR112020006256A2 (pt) 2017-09-29 2020-10-20 Intellia Therapeutics, Inc. método in vitro de administração de mrna usando nanopartículas de lipídio
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
US20190343885A1 (en) 2017-10-31 2019-11-14 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US11591311B2 (en) 2017-11-21 2023-02-28 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
CA3082855A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
WO2019101642A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
CA3082858A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
EP3720494A2 (en) 2017-12-06 2020-10-14 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2019136159A1 (en) * 2018-01-03 2019-07-11 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US11530220B2 (en) 2018-02-06 2022-12-20 Ideaya Biosciences, Inc. Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR
WO2020018848A1 (en) * 2018-07-19 2020-01-23 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using amido compounds
MX2021002215A (es) 2018-08-24 2021-07-15 Jaguahr Therapeutics Pte Ltd Derivados de tetrahidropiridopirimidina como moduladores de ahr.
WO2020043880A1 (en) 2018-08-31 2020-03-05 Jaguahr Therapeutics Pte Ltd Heterocyclic compounds as ahr modulators
EP3847176A1 (en) 2018-09-07 2021-07-14 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compound
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS
CN113272305A (zh) * 2018-10-16 2021-08-17 医肯纳肿瘤学公司 吲哚ahr抑制剂及其用途
US20210379113A1 (en) * 2018-10-31 2021-12-09 Magenta Therapeutics Inc. Methods for hematopoietic stem and progenitor cell transplant therapy
EP4013508A1 (en) 2019-08-12 2022-06-22 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
IL293326A (en) 2019-11-26 2022-07-01 Ikena Oncology Inc Polymorphic Carbazole History and Uses
AU2020400151A1 (en) 2019-12-09 2022-07-14 Otsuka Pharmaceutical Co., Ltd. Acrylamide compounds
US20230279394A1 (en) 2019-12-18 2023-09-07 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
KR20220153595A (ko) 2020-02-26 2022-11-18 재규어 테라퓨틱스 피티이 리미티드 AhR 신호전달의 조절에 유용한 피리도피리미딘 유도체
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US20230279440A1 (en) 2020-05-06 2023-09-07 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
CN115803435A (zh) 2020-05-06 2023-03-14 塞勒克提斯公司 用于在细胞基因组中靶向插入外源序列的方法
US20230279354A1 (en) 2020-07-01 2023-09-07 Nextgem Inc. Human long-term hematopoietic stem cell marker
WO2022029063A1 (en) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
WO2022269518A2 (en) 2021-06-23 2022-12-29 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
WO2023150393A2 (en) 2022-02-07 2023-08-10 Ensoma, Inc. Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
TW202413646A (zh) 2022-07-22 2024-04-01 美商萊爾免疫藥物股份有限公司 免疫細胞療法
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399196A (en) 1959-01-22 1968-08-27 Ciba Geigy Corp Nu-substituted pyrazolo-pyrimidines
DE3150486A1 (de) * 1981-12-19 1983-08-25 Merck Patent Gmbh, 6100 Darmstadt Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5117830A (en) * 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
FR2732604B1 (fr) * 1995-04-07 1997-06-06 Vacsyn Sa Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1133291B1 (en) 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
DK1150982T3 (da) * 1999-02-01 2005-12-27 Cv Therapeutics Inc Purininhibitorer af cylkineafhængig kinase 2 og 1kB-alfa
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CN1110552C (zh) * 1999-07-13 2003-06-04 中国人民解放军第二军医大学 一种体外扩增造血干细胞的新方法
EP1213965B1 (en) 1999-09-10 2006-01-18 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2003509462A (ja) 1999-09-24 2003-03-11 スミスクライン・ビーチャム・コーポレイション トロンボポイエチン模倣物
WO2001034585A1 (en) 1999-11-05 2001-05-17 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
AU2079901A (en) 1999-12-06 2001-06-12 Smithkline Beecham Corporation Thrombopoietin mimetics
DE60028253T2 (de) 1999-12-17 2007-03-08 Ariad Pharmaceuticals, Inc., Cambridge Neue purine
WO2001049688A1 (en) * 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
CA2377666A1 (en) * 2000-07-18 2002-01-24 Minoru Takebe Stem cell reinforcing material
EP1349613A4 (en) 2000-12-19 2005-09-21 Smithkline Beecham Corp THROMBOPOIETINMIMETIKA
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
EP1459758B1 (en) 2001-12-28 2009-02-25 Asubio Pharma Co., Ltd. Cofilin for promoting the proliferation and/or differentiation of hematopoietic stem cells and/or hematopoietic precursor cells
EP1556059A4 (en) 2002-06-06 2010-06-30 Smithkline Beecham MIMETICS OF THROMBOPOIETINE
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2004089068A (ja) * 2002-08-30 2004-03-25 Kobe University Ａｈ受容体リガンド特異的な遺伝子発現誘導因子及びその機能に基づく異種遺伝子誘導発現系の利用技術
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
US20070161582A1 (en) * 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
EP1670795A1 (en) * 2003-09-18 2006-06-21 ALTANA Pharma AG Pharmacologically active imidazo 4,5-c pyridines
CA2548951A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
AP2007003939A0 (en) * 2004-09-03 2007-04-30 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005288858B2 (en) 2004-09-30 2011-04-21 Janssen R&D Ireland HCV inhibiting bi-cyclic pyrimidines
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
AU2005313313A1 (en) * 2004-12-09 2006-06-15 Altana Pharma Ag Substituted imidazo[4,5-b]pyridines as inhibitors of gastric acid secretion
US20060281791A1 (en) * 2005-04-29 2006-12-14 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
CN101213190A (zh) 2005-07-14 2008-07-02 Irm责任有限公司 用作tpo模拟物的化合物和组合物
CN101282929A (zh) 2005-08-15 2008-10-08 Irm责任有限公司 用作tpo模拟物的化合物和组合物
MY146645A (en) * 2006-04-21 2012-09-14 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
MX2008015975A (es) 2006-06-14 2009-03-26 Chugai Pharmaceutical Co Ltd Agentes para promocionar el crecimiento de celulas de vastago hematopoyeticas.
US8372797B2 (en) * 2006-06-22 2013-02-12 Creative Medical Health, Inc. Treatment of erectile dysfunction by stem cell therapy
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
PT2076268E (pt) 2006-10-19 2013-03-07 Genzyme Corp Roscovitina para o tratamento de certas doenças císticas
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
AU2008231695B2 (en) 2007-03-28 2013-03-28 Novartis Ag Purinyl derivatives and their use as potassium channel modulators
ES2494365T3 (es) * 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity

Also Published As

Publication number Publication date
EP3524604B1 (en) 2023-03-29
DOP2011000114A (es) 2017-09-29
MX347834B (es) 2016-10-07
US20100183564A1 (en) 2010-07-22
US8927281B2 (en) 2015-01-06
WO2010059401A2 (en) 2010-05-27
CL2009002010A1 (es) 2010-06-25
CU20110096A7 (es) 2012-01-31
CY1121857T1 (el) 2020-07-31
EA201100663A1 (ru) 2011-12-30
MY155137A (en) 2015-09-15
US20210187033A1 (en) 2021-06-24
PL2350078T3 (pl) 2019-09-30
TN2011000174A1 (en) 2012-12-17
NI201100083A (es) 2011-11-03
MA32828B1 (fr) 2011-11-01
AU2009317898A1 (en) 2010-05-27
CA2740589A1 (en) 2010-05-27
JO3593B1 (ar) 2020-07-05
CN102203096A (zh) 2011-09-28
EA019872B1 (ru) 2014-06-30
CA2943540C (en) 2020-10-27
WO2010059401A3 (en) 2010-09-23
KR101434719B1 (ko) 2014-08-27
CU24495B1 (es) 2021-01-12
US20170239296A1 (en) 2017-08-24
GEP20146053B (en) 2014-03-10
CN102203096B (zh) 2014-09-17
DK2350078T3 (da) 2019-07-15
ES2948567T3 (es) 2023-09-14
BRPI0921799A2 (pt) 2016-01-12
HUE044802T2 (hu) 2019-11-28
US9580426B2 (en) 2017-02-28
IL212368A (en) 2015-02-26
RS59027B1 (sr) 2019-08-30
AU2009317898B2 (en) 2013-07-11
HN2011001195A (es) 2014-01-13
TW201028153A (en) 2010-08-01
AR074063A1 (es) 2010-12-22
CR20110192A (es) 2011-06-10
JP5390626B2 (ja) 2014-01-15
PE20100362A1 (es) 2010-05-27
CA2740589C (en) 2017-11-21
IL212368A0 (en) 2011-06-30
SI2350078T1 (sl) 2019-08-30
SMAP201100024A (it) 2011-07-11
TWI532486B (zh) 2016-05-11
ECSP11011090A (es) 2011-09-30
HRP20191238T1 (hr) 2019-11-29
JP2012507554A (ja) 2012-03-29
PT2350078T (pt) 2019-07-19
EP2350078B1 (en) 2019-04-17
SMP201100024B (it) 2012-03-05
CA3061937A1 (en) 2010-05-27
US20140114070A1 (en) 2014-04-24
SV2011003888A (es) 2011-07-05
ES2736728T3 (es) 2020-01-07
NZ592435A (en) 2013-01-25
CA2943540A1 (en) 2010-05-27
LT2350078T (lt) 2019-07-25
KR20110075042A (ko) 2011-07-05
EP3524604A1 (en) 2019-08-14
EP2350078A2 (en) 2011-08-03
CL2013001874A1 (es) 2014-04-04
BRPI0921799B8 (pt) 2021-05-25
BRPI0921799B1 (pt) 2020-09-29
MX2011004593A (es) 2011-06-16

Similar Documents

Publication Publication Date Title
ECSP11011090A (es) Compuestos que expanden las células madre hematopoiéticas
ECSP18012359A (es) Composiciones ingeribles por abejas, procedimientos para el uso de las mismas para producir miel y miel producida de esta manera
CL2008001620A1 (es) Induccion de fenotipo tolerogenico en celulas dendriticas maduras
BR112013026501A2 (pt) “métodos para preparar um oócito, de fertilização in vitro, e para aumentar a capacidade de geração de atp de um oócito, oócito, e, composição”
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
AR084752A1 (es) Metodos para crioconservar y encapsular celulas
BR112018003031A2 (pt) formulações clínicas
CL2017001903A1 (es) Composición novedosa para uso en el incremento de eficacia de injerto de células madre hematopoyéticas después del trasplante
CO2021003290A2 (es) Método para obtener una población enriquecida de células madre mesenquimales funcionales, células obtenidas de la misma y composiciones que las comprenden.
CO2017004735A2 (es) Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
CL2020001422A1 (es) Terapias con ligandos de proteína tipo lantionina c 2 y células preparadas con ellas
MX2020004811A (es) Métodos y composiciones de reconstrucción no mieloablativa de médula ósea.
WO2012102937A3 (en) Benz imidazole compounds that expand hematopoietic stem cells
CO2020006855A2 (es) Composiciones y métodos para el agotamiento de células cd2+
BR112013028257A2 (pt) "composição de fármaco biológico, métodos de manipulação de uma composição de fármaco biológica com células vivas e de fornecer composições de células vivas em um ponto de instalação de tratamento, bem como uso de células vivas formuladas em tampão não nutritivo"
WO2017015245A8 (en) Methods and compositions for stem cell transplantation
CO2020007275A2 (es) Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas
MX2020004063A (es) Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados.
EA201790883A1 (ru) Толерогенные дендритные клетки, способы их получения и их применения
IN2014DN08964A (es)
UY32209A (es) "compuestos que expanden las células madre hematopoiéticas"
CL2011003355A1 (es) Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras.
CL2016001813A1 (es) Uso de gsk-j4 en la prevención y/o tratamiento del rechazo de trasplantes.
UA103206C2 (ru) Соединения, которые способствуют росту гемотопоэтических стволовых клеток
AR123116A1 (es) Composiciones y métodos para la disminución de células cd117⁺

Legal Events

Date Code Title Description
FC Application refused